KalVista Pharmaceuticals is developing novel plasma kallikrein inhibitors, which represent a new approach to the treatment of DME, the leading cause of adult visual loss in developed countries.
Latest News
KalVista Pharmaceuticals Brings Expertise to New European Consortium Focused on the Discovery and Development of Novel Eye Therapeutics
KalVista Pharmaceuticals Wins £2.4m Biomedical Catalyst Grant to Further Develop Oral Plasma Kallikrein Inhibitors as a Treatment for Diabetic Macular Edema
|
KalVista Pharmaceuticals is an ophthalmology company with a focus on diabetic macular edema
Kalvista Pharmaceuticals Ltd
Building 227
Tetricus Science Park
Porton Down
SP4 0JQ
United Kingdom
t: +44 1980 753002
e: info@kalvista.com
All content © copyright KalVista Pharmaceuticals. All rights reserved 2013.